All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The U. S. Food and Drug Administration (FDA) has granted orphan drug designation to AB8939 for the treatment of patients with acute myeloid leukemia (AML).1 AB8939 was shown to offer therapeutic benefit in refractory/relapsed AML.
AB8939 is a novel tubulin inhibitor which seems able to overcome drug resistance induced by P-glycoprotein (Pgp). It acts by binding to the colchicine-binding site of the beta-subunit of tubulin, leading to apoptosis via mitotic cell cycle arrest at the G2/M phase. Unlike vinca alkaloids (e.g. vincristine or vinblastine), AB8939 is not deactivated by myeloperoxidase and has been shown to have a strong anti-proliferative effect in refractory/resistant AML cell lines.2 Data on this will be presented at the 61st Annual Meeting and Exposition of the American Society of Hematology which will take place in Orlando, US, on the 7–10th December 2019.
Orphan drug status grants a company with a seven-year exclusivity period for marketing and allows the company to apply for funding for phase I and II clinical trials, providing some financial benefits and a quicker regulatory process further down the line.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox